Genomics of Emerging Infectious Disease: A PLoS Collection

Editorial Genomics of Emerging Infectious Disease: A PLoS Collection Jonathan A. Eisen 1 *, Catriona J. MacCallum 2 * 1 University of California Davis, Davis, California, United States of America, 2 Public Library of Science, Cambridge, United Kingdom Today, the Public Library of Science publishes a collection of essays, perspectives, and reviews about how genomics, with all its associated tools and techniques, can provide insights into our understanding of emerging infectious disease (http://ploscollections. org/emerginginfectiousdisease/) [1–13]. This collection, focused on human disease, is particularly timely as pandemic H1N1 2009 influenza (commonly referred to as swine flu) spreads around the globe, and government officials, the public, journalists, bloggers, and tweeters strive to find out more. People want to know if this flu poses more of a threat than other seasonal flu strains, how fast it’s spreading (and where), and what can be done to contain it. As this collection illustrates, the increasing speed at which complete genome sequences and other genome-scale data can be generated for individual isolates and strains of a pathogen provides tremendous opportunities to identify the molecular changes in these disease agents that will enable us to track their spread and evolution through time (e.g., [3,7,8]) and generate the vaccines and drugs necessary to combat them (e.g., [5–7]). The collection also shines a spotlight on specific pathogens, some familiar and widespread, such as the influenza A virus (e.g., [9]); some ‘‘reemerging,’’ such as the Mycobacterium tuberculosis complex that causes tuberculosis [10]; and some identified only recently, as with the bacterium Helicobacter pylori (which causes peptic ulcers and gastric cancer [11]). There is no simple definition of an emerging disease, but it can be loosely described as a disease that is novel in some way—for example, one that displays a change in geographic location, genetics, or function. Emerging infectious diseases are caused by a wide range of organisms, but they are perhaps best typified by zoonotic viral diseases that cross from animal to human hosts and can have a devastating impact on human health, causing a high disease burden and mortality [8]. These zoonotic diseases include monkeypox, Hendra virus, Nipah virus, and severe acute respiratory syndrome coronavirus (SARS-CoV), in addition to influenza A and the lentiviruses that cause AIDS. The apparently increased transmission of pathogens from animals to humans over the recent decades has been attributed to the unintended consequences of globalization as well as environmental factors and changes in agricultural practices [8]. Generally, the burden of these diseases is most strongly felt by those in developing countries. Brindley et al. [12] point to the debilitating effects of the most common human infectious agent in such areas—helminths (parasitic worms)—and the role that genomics plays in advancing our understanding of molecular and medical helminthology. Compounding the problem of emerging infectious diseases in developing countries is the reality that researchers in developing countries have often been unable to participate fully in genomics research, because of their technological isolation and limited resources. As Harris et al. emphasize [13], ‘‘collaborations— starting with capacity building in genomics research—need to be fostered so that countries that are currently excluded from the genomics revolution find an entry point for participation.’’ This collection is a collaborative effort that combines financial support from Google.org (which has also sponsored research on PLoS Biology | www.plosbiology.org emerging infectious disease through its Predict and Prevent initiative [14]) with PLoS’s editorial independence and rigor. Gupta et al. [1] provide Google.org’s perspective and vision for how systematic application of genomics, proteomics, and bioinfor- matics to infectious diseases could predict and prevent the next pandemic. To realize this vision, they urge the community to unite under an ‘‘Infectious Disease Genomics Project,’’ analogous to the Human Genome Project. This is, as the authors admit, a potentially ‘‘grandiose’’ and difficult proposition. Some researchers might justifiably argue that much is already being achieved—as demonstrated by this collection—and that the vision is nai ve. However, as every article in the collection also points out, tremendous challenges remain if the potential of genomics in this field is to be realized. One problem is that, despite the fact that sequencing is now the method of choice for characterizing new disease agents, and new substantially faster and cheaper sequencing methods are contin- ually being produced, we still lack the range of computational tools necessary to analyze these sequences in sufficient detail [4]. It is possible to sequence the entire assemblage of viruses in a particular tissue type or host species [3] and to obtain complete or nearly complete genome sequences for large samples of bacteria [7]. Yet we remain in the early, albeit essential, stages of pathogen discovery (Box 1). These sequences can be interpreted fully only when integrated with relevant environmental, epidemiological, and clinical data (e.g., [3,4,8]). And, despite the increased sequencing, really comprehensive genome data are still only available for a few key pathogens, which further limits our understanding. For example, a full quantitative understanding of the processes that shape the epidemiology and evolution—the phylodynamics—of RNA viruses is currently possible only for HIV and influenza A virus [3]. In this collection, you will find not only the views of leading researchers from several different disciplines, and a provocative vision from a funding agency, but also the contributions of six different PLoS journals (PLoS Biology, PLoS Medicine, PLoS Computational Biology, PLoS Genetics, PLoS Neglected Tropical Diseases, and PLoS Pathogens). The PLoS open-access model of publishing makes possible such a large multidisciplinary cross-journal collection, in which all articles are simultaneously available online Citation: Eisen J, MacCallum CJ (2009) Genomics of Emerging Infectious Disease: A PLoS Collection. PLoS Biol 7(10): e1000224. doi:10.1371/journal.pbio.1000224 Published October 26, 2009 Copyright: s 2009 Eisen, MacCallum. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Competing Interests: The authors have declared that no competing interests exist. * E-mail: jaeisen@ucdavis.edu (JAE); cmaccallum@plos.org (CJM) This article is part of the ‘‘Genomics of Emerging Infectious Disease’’ PLoS Journal collection (http://ploscollections.org/emerginginfectiousdisease/). October 2009 | Volume 7 | Issue 10 | e1000224

[1]  Rajesh Gupta,et al.  Can an Infectious Disease Genomics Project Predict and Prevent the Next Pandemic? , 2009, PLoS biology.

[2]  N. Salama,et al.  Helicobacter pylori's Unconventional Role in Health and Disease , 2009, PLoS pathogens.

[3]  G. Dougan,et al.  The Key Role of Genomics in Modern Vaccine and Drug Design for Emerging Infectious Diseases , 2009, PLoS genetics.

[4]  A. Osterhaus,et al.  The Application of Genomics to Emerging Zoonotic Viral Diseases , 2009, PLoS pathogens.

[5]  Makedonka Mitreva,et al.  Helminth Genomics: The Implications for Human Health , 2009, PLoS neglected tropical diseases.

[6]  I. Comas,et al.  The Past and Future of Tuberculosis Research , 2009, PLoS pathogens.

[7]  A. Mchardy,et al.  The Role of Genomics in Tracking the Evolution of Influenza A Virus , 2009, PLoS pathogens.

[8]  Jacques Ravel,et al.  The Role of Genomics in the Identification, Prediction, and Prevention of Biological Threats , 2009, PLoS biology.

[9]  E. Harris,et al.  Molecular Genomic Approaches to Infectious Diseases in Resource-Limited Settings , 2009, PLoS medicine.

[10]  D. Falush Toward the Use of Genomics to Study Microevolutionary Change in Bacteria , 2009, PLoS genetics.

[11]  Edward C. Holmes,et al.  Discovering the Phylodynamics of RNA Viruses , 2009, PLoS Comput. Biol..

[12]  Siv G. E. Andersson,et al.  Computational Resources in Infectious Disease: Limitations and Challenges , 2009, PLoS Comput. Biol..

[13]  Wim G. J. Hol,et al.  The Role of Medical Structural Genomics in Discovering New Drugs for Infectious Diseases , 2009, PLoS Comput. Biol..

[14]  Rino Rappuoli,et al.  Vaccinology in the genome era. , 2009, The Journal of clinical investigation.

[15]  Brian Pease,et al.  Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography† , 2009, Journal of medicinal chemistry.

[16]  T. Willson,et al.  Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.

[17]  Kristina M Smith,et al.  Native chromatin immunoprecipitation (N-ChIP) and ChIP-Seq of Schistosoma mansoni: Critical experimental parameters. , 2009, Molecular and biochemical parasitology.

[18]  Gavin J. D. Smith,et al.  Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic , 2009, Nature.

[19]  K. Jansen,et al.  Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. , 2009, Vaccine.

[20]  R. Jacobson,et al.  Application of pharmacogenomics to vaccines. , 2009, Pharmacogenomics.

[21]  M. Taussig,et al.  Protein microarrays: high-throughput tools for proteomics , 2009, Expert review of proteomics.

[22]  B. Staels,et al.  Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens , 2009, Nature.

[23]  C. Schulze-Briese,et al.  Crystal structure of Ultralente—A microcrystalline insulin suspension , 2009, Proteins.

[24]  Ruben Abagyan,et al.  Structure‐Based Approaches to Antibiotic Drug Discovery , 2009, Current protocols in microbiology.

[25]  J. Kawai,et al.  Direct Metagenomic Detection of Viral Pathogens in Nasal and Fecal Specimens Using an Unbiased High-Throughput Sequencing Approach , 2009, PloS one.

[26]  S. Miller,et al.  The role of infections in autoimmune disease , 2009, Clinical and experimental immunology.

[27]  A. Fenwick Host-parasite relations and implications for control. , 2009, Advances in parasitology.

[28]  I. Margarit,et al.  Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. , 2009, The Journal of infectious diseases.

[29]  Akane Kawamura,et al.  Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. , 2008, Toxicology.

[30]  J. Musser,et al.  Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. , 2008, The Journal of infectious diseases.

[31]  S. Ram,et al.  Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera , 2008, Infection and Immunity.

[32]  Andrew D. Hamilton,et al.  alpha-Helix mimetics as inhibitors of protein-protein interactions. , 2008, Biochemical Society transactions.

[33]  L. Pena,et al.  Deceptive imprinting and immune refocusing in vaccine design. , 2008, Vaccine.

[34]  Yoav Freund,et al.  Image-based crystal detection: a machine-learning approach , 2008, Acta crystallographica. Section D, Biological crystallography.

[35]  Rino Rappuoli,et al.  Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.

[36]  P. Nollert,et al.  The plug-based nanovolume Microcapillary Protein Crystallization System (MPCS) , 2008, Acta crystallographica. Section D, Biological crystallography.

[37]  R. Rappuoli,et al.  Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37 , 2008, Infection and Immunity.

[38]  Julie McMurry,et al.  Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. , 2008, Current opinion in pharmacology.

[39]  Gangqiao Zhou,et al.  Infectious disease in the genomic era. , 2008, Annual review of genomics and human genetics.

[40]  M. Marra,et al.  Applications of next-generation sequencing technologies in functional genomics. , 2008, Genomics.

[41]  A. Bhagwat,et al.  Methods and tools for comparative genomics of foodborne pathogens. , 2008, Foodborne pathogens and disease.

[42]  J. Sarles,et al.  Molecular Detection of Multiple Emerging Pathogens in Sputa from Cystic Fibrosis Patients , 2008, PloS one.

[43]  J. Wain,et al.  High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi , 2008, Nature Genetics.

[44]  P. Gajer,et al.  The Pangenome Structure of Escherichia coli: Comparative Genomic Analysis of E. coli Commensal and Pathogenic Isolates , 2008, Journal of bacteriology.

[45]  William Martin,et al.  Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety , 2008, Clinical Applications of Immunomics.

[46]  D. Granoff,et al.  Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. , 2008, The Journal of infectious diseases.

[47]  Chao Zhang,et al.  An integrated platform of genomic assays reveals small-molecule bioactivities. , 2008, Nature chemical biology.

[48]  Lei Tang,et al.  Shape shifting leads to small-molecule allosteric drug discovery. , 2008, Chemistry & biology.

[49]  William Martin,et al.  Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. , 2008, Vaccine.

[50]  A. Kusalik,et al.  Massive peptide sharing between viral and human proteomes , 2008, Peptides.

[51]  D. K. Kaushik,et al.  Developing Antibacterial Vaccines in Genomics and Proteomics Era , 2008, Scandinavian journal of immunology.

[52]  C. Donati,et al.  A Second Pilus Type in Streptococcus pneumoniae Is Prevalent in Emerging Serotypes and Mediates Adhesion to Host Cells , 2008, Journal of bacteriology.

[53]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[54]  Jianli Dong,et al.  Emerging Pathogens: Challenges and Successes of Molecular Diagnostics , 2008, The Journal of Molecular Diagnostics.

[55]  R. Vierkant,et al.  Human Leukocyte Antigen and Cytokine Receptor Gene Polymorphisms Associated With Heterogeneous Immune Responses to Mumps Viral Vaccine , 2008, Pediatrics.

[56]  P. Nordlund,et al.  The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins. , 2008, Protein expression and purification.

[57]  S. Ram,et al.  Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. , 2008, The Journal of infectious diseases.

[58]  Yanhui Hu,et al.  Production and sequence validation of a complete full length ORF collection for the pathogenic bacterium Vibrio cholerae , 2008, Proceedings of the National Academy of Sciences.

[59]  M. Kalin,et al.  Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies , 2008, The Journal of experimental medicine.

[60]  Mark Harris,et al.  Data management in structural genomics: an overview. , 2008, Methods in molecular biology.

[61]  David Baker,et al.  Structural genomics of pathogenic protozoa: an overview. , 2008, Methods in molecular biology.

[62]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[63]  Rino Rappuoli,et al.  Bridging the knowledge gaps in vaccine design , 2007, Nature Biotechnology.

[64]  E. Winzeler,et al.  Genomics, systems biology and drug development for infectious diseases. , 2007, Molecular bioSystems.

[65]  K. Reynolds,et al.  Antibacterial targets in fatty acid biosynthesis. , 2007, Current opinion in microbiology.

[66]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[67]  D. O'Kane,et al.  Translation of Pharmacogenetics into Clinically Relevant Testing Modalities , 2007, Clinical pharmacology and therapy.

[68]  M. Katze,et al.  Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV–Infected Macaques , 2007, PLoS pathogens.

[69]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[70]  D. Dimitrov,et al.  Structure and Function of the HIV Envelope Glycoprotein as Entry Mediator, Vaccine Immunogen, and Target for Inhibitors , 2007, Advances in Pharmacology.

[71]  E. Querol,et al.  Pathogen Proteins Eliciting Antibodies Do Not Share Epitopes with Host Proteins: A Bioinformatics Approach , 2007, PloS one.

[72]  R. Rappuoli,et al.  The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. , 2007, Drug discovery today.

[73]  Pierre Baldi,et al.  Immunodominant Francisella tularensis antigens identified using proteome microarray. ©Crown Copyright 2007 Dstl , 2007, Proteomics.

[74]  E. Davioud‐Charvet,et al.  Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.

[75]  D. Kanduc,et al.  Non-redundant peptidomes from DAPs: towards "the vaccine"? , 2007, Autoimmunity reviews.

[76]  K. Lundstrom,et al.  Structural genomics and drug discovery , 2007, Journal of cellular and molecular medicine.

[77]  J. Casanova,et al.  Human genetics of infectious diseases: a unified theory , 2007, The EMBO journal.

[78]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[79]  A. Goldman,et al.  A complete structural description of the catalytic cycle of yeast pyrophosphatase. , 2007, Biochemistry.

[80]  Haruki Nakamura,et al.  The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data , 2006, Nucleic Acids Res..

[81]  M. Pucci Novel Genetic Techniques and Approaches in the Microbial Genomics Era , 2007, Drugs in R&D.

[82]  Julius Rebek,et al.  Heterocyclic alpha-helix mimetics for targeting protein-protein interactions. , 2007, Bioorganic & medicinal chemistry letters.

[83]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[84]  R. Rappuoli,et al.  Streptococcus pneumoniae Pilus Subunits Protect Mice against Lethal Challenge , 2006, Infection and Immunity.

[85]  D. Erlanson Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[86]  George T Detitta,et al.  Thermofluor-based high-throughput stability optimization of proteins for structural studies. , 2006, Analytical biochemistry.

[87]  T. Earnest,et al.  Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. , 2006, Journal of medicinal chemistry.

[88]  Jenefer M Blackwell,et al.  Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? , 2006, The Lancet Infectious Diseases.

[89]  R. Rappuoli,et al.  A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Rino Rappuoli,et al.  Pili in Gram-positive pathogens , 2006, Nature Reviews Microbiology.

[91]  David H Perlman,et al.  The Meningococcal Vaccine Candidate GNA1870 Binds the Complement Regulatory Protein Factor H and Enhances Serum Resistance , 2006, The Journal of Immunology.

[92]  S. D. Mills When will the genomics investment pay off for antibacterial discovery? , 2006, Biochemical pharmacology.

[93]  Dong Hui Xu,et al.  Automated classification of protein crystallization images using support vector machines with scale-invariant texture and Gabor features. , 2006, Acta crystallographica. Section D, Biological crystallography.

[94]  R. Rappuoli,et al.  A pneumococcal pilus influences virulence and host inflammatory responses. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[95]  G. Bensi,et al.  Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome , 2006, Nature Biotechnology.

[96]  Paul Kellam,et al.  Attacking pathogens through their hosts , 2006, Genome Biology.

[97]  G. Grandi Genomics and proteomics in reverse vaccines. , 2005, Methods of biochemical analysis.

[98]  Daniela Barlocco,et al.  Privileged structures as leads in medicinal chemistry. , 2006, Current medicinal chemistry.

[99]  G. Bensi,et al.  Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Christoph Dehio,et al.  Signature-tagged mutagenesis: technical advances in a negative selection method for virulence gene identification. , 2005, Current opinion in microbiology.

[101]  Jaideep P. Sundaram,et al.  Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[102]  D. Butler Flu researchers slam US agency for hoarding data , 2005, Nature.

[103]  H. Tettelin,et al.  Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen , 2005, Science.

[104]  R. Rappuoli,et al.  Genome Analysis Reveals Pili in Group B Streptococcus , 2005, Science.

[105]  Stephen H Hughes,et al.  Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2005, Progress in biophysics and molecular biology.

[106]  Russell L. Marsden,et al.  Progress of structural genomics initiatives: an analysis of solved target structures. , 2005, Journal of molecular biology.

[107]  M. Hanner,et al.  Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. , 2005, Vaccine.

[108]  R. Rappuoli,et al.  The impact of genomics on vaccine design. , 2005, Trends in biotechnology.

[109]  Bjoern Peters,et al.  A roadmap for the immunomics of category A-C pathogens. , 2005, Immunity.

[110]  M. Rossmann,et al.  Design, expression, and purification of a Flaviviridae polymerase using a high‐throughput approach to facilitate crystal structure determination , 2004, Protein science : a publication of the Protein Society.

[111]  D. Pei,et al.  Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size. , 2004, Journal of medicinal chemistry.

[112]  C. Martínez-A,et al.  Statins Inhibit HIV-1 Infection by Down-regulating Rho Activity , 2004, The Journal of experimental medicine.

[113]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[114]  Takayoshi Kinoshita,et al.  Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. , 2004, Journal of medicinal chemistry.

[115]  J. Strohbach,et al.  Non-peptidic HIV protease inhibitors. , 2004, Current topics in medicinal chemistry.

[116]  M. Root,et al.  HIV-1 gp41 as a target for viral entry inhibition. , 2004, Current pharmaceutical design.

[117]  Rick Lyons,et al.  The temporal expression profile of Mycobacterium tuberculosis infection in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Robert E. Thorne,et al.  Microfabricated mounts for high-throughput macromolecular cryocrystallography , 2003 .

[119]  M. Goldman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Vaccination and Autoimmune Disease: What Is the Evidence? , 2022 .

[120]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[121]  P. Lam,et al.  Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. , 2003, Journal of medicinal chemistry.

[122]  R. Ismagilov,et al.  Screening of protein crystallization conditions on a microfluidic chip using nanoliter-size droplets. , 2003, Journal of the American Chemical Society.

[123]  Rodrigo Lopez,et al.  Multiple sequence alignment with the Clustal series of programs , 2003, Nucleic Acids Res..

[124]  R. Haas,et al.  Identification and Characterization of Helicobacter pylori Genes Essential for Gastric Colonization , 2003, The Journal of experimental medicine.

[125]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[126]  Joseph R Luft,et al.  A deliberate approach to screening for initial crystallization conditions of biological macromolecules. , 2003, Journal of structural biology.

[127]  Jeannette Adu-Bobie,et al.  Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 , 2003, The Journal of experimental medicine.

[128]  S. Quake,et al.  A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[129]  Julie Wilson,et al.  Towards the automated evaluation of crystallization trials. , 2002, Acta crystallographica. Section D, Biological crystallography.

[130]  Y. Kiso,et al.  HIV protease inhibitors: peptidomimetic drugs and future perspectives. , 2002, Current medicinal chemistry.

[131]  S. Harrison,et al.  Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[132]  W. Hol,et al.  Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. , 2002, Journal of the American Chemical Society.

[133]  L. Huber,et al.  Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis , 2002, Proteomics.

[134]  Earl W. Cornell,et al.  An approach to rapid protein crystallization using nanodroplets , 2002 .

[135]  R. Rappuoli,et al.  Reverse vaccinology, a genome-based approach to vaccine development. , 2001 .

[136]  D. O'Kane,et al.  Gene expression microarrays: a 21st century tool for directed vaccine design. , 2001, Vaccine.

[137]  Christoph M Tang,et al.  Functional genomics of Neisseria meningitidis pathogenesis , 2000, Nature Medicine.

[138]  M. Gelb,et al.  Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine. , 2000, Journal of medicinal chemistry.

[139]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[140]  J. Wood,et al.  Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. , 2000, Chemistry & biology.

[141]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[142]  Stuart L. Schreiber,et al.  Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements , 1999, Nature Structural Biology.

[143]  A. Goldman,et al.  Evolutionary aspects of inorganic pyrophosphatase , 1999, FEBS letters.

[144]  M. Gelb,et al.  Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. , 1998, Journal of medicinal chemistry.

[145]  A. Steere,et al.  Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. , 1998, Science.

[146]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[147]  N. Chirgadze,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[148]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[149]  M. Rossmann,et al.  The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle. , 1997, Structure.

[150]  W G Laver,et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.

[151]  Structure of Escherichia coli inorganic pyrophosphatase at 2.2 A resolution. , 1996, Acta crystallographica. Section D, Biological crystallography.

[152]  R. Fleischmann,et al.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.

[153]  M. Garneau,et al.  A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo , 1994, Nature.

[154]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[155]  W G Laver,et al.  Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. , 1994, Journal of molecular biology.

[156]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[157]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[158]  D. Lipman,et al.  National Center for Biotechnology Information , 2019, Springer Reference Medizin.

[159]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[160]  John P. Overington,et al.  X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.

[161]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[162]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[163]  J. Felsenstein Phylogenies from molecular sequences: inference and reliability. , 1988, Annual review of genetics.

[164]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.